Aurobindo Pharma informs about completion of US FDA inspection

26 Jul 2023 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: The United States Food and Drug Administration (US FDA) inspected the Unit I, a Formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, situated at Koltur Village, Shameerpet, Medchal District, Telangana, from 17th July to 26thth July 2023. The inspection closed with zero observations and a classification of No Action Indicated (NAI).

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1143.70 22.05 (1.97%)
22-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1374.60
Zydus Lifesciences 883.85
Lupin 2165.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×